Free Trial

Arcutis Biotherapeutics (ARQT) News Today

$9.75
-0.02 (-0.20%)
(As of 07/19/2024 ET)
Arcutis Biotherapeutics logo with Medical background
Susquehanna Fundamental Investments LLC Acquires New Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Susquehanna Fundamental Investments LLC bought a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 120,493 shares of the company's stock, valued at approximatel
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up to $10.02
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 9.3%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 9.3%
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Jennison Associates LLC
Jennison Associates LLC lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 34.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,176,315 shares of the company's stock after purchasin
The 7 Best Under $10 Stocks to Buy in July 2024
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.3%
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.3%
Arcutis Biotherapeutics logo with Medical background
AMI Asset Management Corp Buys Shares of 345,239 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
AMI Asset Management Corp bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 345,239 shares of the company's stock, va
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Up 5.6% in June
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 26,020,000 shares, an increase of 5.6% from the May 31st total of 24,640,000 shares. Based on an average daily trading volume, of 2,980,000 shares, the short-interest ratio is currently 8.7 days.
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells $93,100.00 in Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard G. Welgus sold 10,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $9.31, for a total transaction of $93,100.00. Following the transaction, the director now directly owns 180,339 shares in the company, valued at approximately $1,678,956.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.5%
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.5%
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 5.1%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5.1%
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.5% Higher
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 4.5%
Arcutis Biotherapeutics logo with Medical background
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to t
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Up 11.1% in May
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 24,640,000 shares, an increase of 11.1% from the May 15th total of 22,170,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the days-to-cover ratio is currently 7.7 days.
Opaleye Management Inc. Makes New $6.33 Million Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Opaleye Management Inc. acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,960,000 shares of the company's stock, v
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.6% Higher
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.6%
ADAR1 Capital Management LLC Buys New Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
ADAR1 Capital Management LLC purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 275,000 shares of the company's stock, valued at approx
Pennant Investors LP Takes $552,000 Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Pennant Investors LP bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 170,900 shares of the compan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is Pivotal bioVenture Partners Investment Advisor LLC's 7th Largest Position
Pivotal bioVenture Partners Investment Advisor LLC increased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 72.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,910,009 shares of the company's stock after purchasing
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 3.8%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 Shares
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 23,000 shares of the business's stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the transaction, the insider now directly owns 209,793 shares of the company's stock, valued at approximately $1,835,688.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.2%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.2%
Franklin Resources Inc. Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Franklin Resources Inc. grew its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 260.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655,544 shares of the co
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5%
GW&K Investment Management LLC Lowers Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
GW&K Investment Management LLC lessened its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 20.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,640,325 shares of the company's s
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 3.7% Higher
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.7%
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) SVP Larry Todd Edwards Sells 7,640 Shares
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) SVP Larry Todd Edwards sold 7,640 shares of the business's stock in a transaction on Friday, May 17th. The shares were sold at an average price of $8.98, for a total transaction of $68,607.20. Following the transaction, the senior vice president now directly owns 140,360 shares in the company, valued at $1,260,432.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.8%
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
Arcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Beats Estimates By $0.28 EPS
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.28. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative return on equity of 294.85%. The company had revenue of $49.57 million during the quarter. During the same period in the prior year, the firm posted ($1.31) earnings per share.
Get Arcutis Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.

China Stockpiling Gold “Like No Tomorrow” (Ad)

For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .

Click here now to get your free 'De-Dollarization' Guide.

ARQT Media Mentions By Week

ARQT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARQT
News Sentiment

1.01

0.75

Average
Medical
News Sentiment

ARQT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARQT Articles
This Week

5

5

ARQT Articles
Average Week

Get Arcutis Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ARQT) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners